基于杆状病毒表达VP2的候选疫苗对犊牛8型流行性出血病病毒提供完全保护
研究将10头荷斯坦-弗里生犊牛随机分为疫苗接种组(n=5)和对照组(n=5),接种组间隔21天接受两剂200 μg重组VP2蛋白,对照组模拟接种。加强免疫后14天以EHDV-8野毒株攻击,接种组无临床症状和病毒血症,对照组全部出现病毒血症、轻度临床症状和EHDV特异性抗体。
要点
- rVP2候选疫苗耐受良好,仅出现短暂低度发热和轻微局部反应。
- 接种犊牛在接种后第28天产生中和抗体,攻击后无临床症状和病毒血症。
- 接种动物攻击后VP7 ELISA仍为阴性,表明具有DIVA鉴别能力。
核心结论
- rVP2亚单位疫苗在实验条件下对犊牛EHDV-8提供完全保护,表明其可用于疾病控制策略的可能性。
研究设计与样本
- 研究将10头荷斯坦-弗里生犊牛随机分为疫苗接种组(n=5)和对照组(n=5)。
- 接种组间隔21天接受两剂200 μg重组VP2蛋白,对照组模拟接种。
- 加强免疫后14天两组均以EHDV-8野毒株攻击,每日记录临床症状并定期采血评估病毒血症和免疫应答。
主要发现
- rVP2候选疫苗耐受良好,仅出现短暂低度发热和轻微局部反应。
- 接种犊牛在接种后第28天产生中和抗体,接种后第35天EHDV-8攻击后无临床症状和病毒血症。
- 对照组全部犊牛在攻击后出现病毒血症、轻度临床症状和EHDV特异性抗体。
- 接种动物攻击后VP7 ELISA仍为阴性,表明疫苗阻止了病毒复制并具备DIVA能力。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epizootic hemorrhagic disease virus serotype 8 (EHDV-8) has recently emerged in Europe, causing widespread outbreaks in cattle and wild ruminant populations. The lack of commercial vaccines at the time of emergence highlighted the urgent need to develop effective vaccines for disease control. Therefore, we developed and evaluated the safety and efficacy of a novel subunit candidate vaccine against EHDV-8, based on the recombinant VP2 protein (rVP2) from EHDV-8 expressed in a baculovirus system. Ten Holstein-Friesian calves were randomly assigned to vaccinated (n = 5) or control (n = 5) groups. Animals in the vaccinated group received two doses of 200 μg of rVP2 protein 21 days apart, while control animals were sham-vaccinated. Fourteen days after the booster dose, both groups were challenged with a field strain of EHDV-8. Clinical signs were recorded daily, and blood samples were collected at regular intervals to assess viremia and immune response. The rVP2 vaccine candidate was well tolerated, with only transient, low-grade fever and mild local reactions. Vaccinated calves developed neutralizing antibodies by day 28 post-vaccination and, upon EHDV-8 challenge on day 35 post-vaccination, showed no clinical signs or viremia. In contrast, all control calves developed viremia, mild clinical signs, and EHDV-specific antibodies after challenge. Notably, vaccinated animals remained negative by VP7 ELISA even post-challenge, indicating that the rVP2-based vaccine afforded protection from viral replication and disease and enabled DIVA (Differentiating Infected from Vaccinated Animals) capability. In conclusion, these results demonstrate that the rVP2-based subunit vaccine confers complete protection from EHDV-8 under experimental conditions in cattle, indicating the possibility of its use for disease control strategies.
引用
- Spedicato M, Profeta F, Li Y, et al. Vaccine candidate based on a baculovirus expressed VP2 provides full protection from epizootic hemorrhagic disease virus serotype 8 in calves. Vaccine. 2025. PMID: 41289624. doi:10.1016/j.vaccine.2025.128000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。